TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Use of GLP-1 drugs has grown in Great Britain, while UK hair-loss product sales rose 32% in the year to the end of August, according to figures cited by Cosmetics Business. A BMJ-published study reported an association between GLP-1 drugs and increased hair-loss risk, though researchers described the absolute risk as low. Novo Nordisk has announced an intention to enter hair-loss treatment, but details of its plans were not provided in the source report.
Hair-loss products in the UK grew 32% in the year to the end of August, as use of GLP-1 weight-loss drugs rose in Great Britain and research reported a link between the medicines and increased hair-loss risk. The figures, reported by Cosmetics Business and attributed to Worldpanel by Numerator and a study published in the British Medical Journal, point to a possible new demand driver for hair care, although the reported drug-related risk is low in absolute terms.
Worldpanel by Numerator data cited in the report show that the share of Great Britain households using GLP-1 drugs rose from 2.3% in 2024 to 4.1% in 2025 and 6.3% in 2026. The source does not state the precise 2026 measurement period. The figures refer to household use, not the proportion of individuals taking a medication.
Separately, the report says UK hair-loss products grew 32% in the year ending in late August. Worldpanel by Numerator is cited as the source for the sales estimate. Cosmetics Business says the increase is likely correlated with higher GLP-1 use, but the information provided does not establish that the drugs caused the rise in sales or quantify how much demand is attributable to their use.
The report also describes a BMJ-published study that found an association between GLP-1 drugs and increased hair-loss risk. It says the researchers characterized the absolute risk as low and suggested that awareness of the possible effect could inform treatment decisions. The report gives no study title, sample size, drug-specific risk estimates or details about how the research assessed causation.
A New Demand Driver for Hair Care
The figures bring together two developments affecting consumers and the beauty industry: greater reported use of GLP-1 medicines and rising sales of products marketed for hair loss. For people considering or taking these drugs, the study’s reported association adds a potential side effect to discuss with a health professional, rather than proving that hair shedding will occur.
For companies, the trend may create opportunities in products positioned around thinning, strengthening and hair loss. Those categories already existed before the increase in GLP-1 use, the source report notes. The sales growth and the research could influence product development and marketing, but neither by itself shows that a particular hair-care product prevents or treats drug-associated hair loss.
Novo Nordisk, the maker of Ozempic, has announced an intention to enter the hair-loss treatment market, according to Cosmetics Business. That makes the issue relevant beyond traditional cosmetics brands, though the source extract does not specify the form, timing or evidence behind any planned product.
Popular right now
Bose QuietComfort Wireless Noise-Cancelling Over-Ear Headphones, Black
Breville Bambino Espresso Machine, Brushed Stainless Steel
Dyson Ball Animal Total Clean Upright Vacuum
As an affiliate, we earn on qualifying purchases.
GLP-1 Use and Hair-Loss Research
Semaglutide and tirzepatide are GLP-1 medicines. The source report names Ozempic, Mounjaro and Wegovy among the drugs whose use has become more mainstream. It frames hair shedding as a less desirable possible effect alongside weight loss, while noting that discussion of the relationship had initially been anecdotal.
The reported BMJ study adds research evidence of an association, but an association does not establish that a medicine directly caused hair loss in each case. The article extract does not provide enough methodological detail to assess the strength or limits of the finding. Separately, existing hair products have long been marketed for volume, thickness and strength; the development described is a potential shift in demand, not the creation of a new product category.
“The absolute risk is low.”
— Researchers in the study described by Cosmetics Business
What the Sales and Study Do Not Show
The available information does not establish that GLP-1 use caused the 32% sales increase. It provides no survey of why consumers bought hair-loss products, nor a comparison with other possible influences on sales. The household-use figures also do not reveal how many people took a drug, which medicines they used or how long they used them.
The BMJ study’s design, population, follow-up period and absolute risk estimates are absent from the supplied report. It is consequently unclear how the reported association varies by medication or patient group, or how it compares with other potential causes of hair shedding. The source also does not explain what Novo Nordisk plans to develop, when it might do so, or whether it refers to a medicine or another type of treatment.
Evidence and Product Plans to Watch
Further detail on the BMJ study would help readers and clinicians interpret the reported risk, including its methods, patient population and drug-specific results. The source report does not identify a scheduled follow-up study or a forthcoming regulatory decision.
For the market, the next useful indicators will be updated GLP-1 use and hair-care sales data, alongside any specific announcement from Novo Nordisk about its hair-loss plans. Until those details emerge, the reported sales growth should be treated as a market trend that may be related to rising medication use, not proof that GLP-1 drugs are driving the increase.
Key Questions
Does the reported research prove GLP-1 drugs cause hair loss?
No. Cosmetics Business describes the BMJ-published research as finding an association with increased risk. The supplied report does not establish causation, and it says the absolute risk is low.
How much did UK hair-loss product sales grow?
Worldpanel by Numerator, as cited by Cosmetics Business, estimated 32% growth in the year to the end of August. The source extract does not specify a sales value or a breakdown by product.
How common was GLP-1 use in Great Britain?
The report says the share of households using GLP-1 drugs rose from 2.3% in 2024 to 4.1% in 2025 and 6.3% in 2026. It does not state the precise period measured in 2026.
Is Novo Nordisk launching a hair-loss product?
The source says Novo Nordisk announced an intention to enter hair-loss treatment, but provides no product details, launch timetable or confirmation of what form the treatment would take.
Source: cosmeticsbusiness.com
